Doximity stock reacts to earnings miss and legal investigation

Doximity (DOCS) is under pressure after May 13, 2026 financial results missed revenue expectations and management flagged near term margin pressure from AI spending. Shares dropped 23% and a law firm is probing potential securities law violations.

That steep one day drop sits on top of a longer slide, with the 30 day share price return down 24.31% and the year to date share price return down 53.75%, while the 1 year total shareholder return has declined 64.85%. This points to fading momentum as investors reassess growth prospects and legal risks.

If this kind of healthcare AI story has your attention, it can be useful to compare it with other early leaders in the space using our screener of 40 healthcare AI stocks

With Doximity now trading at US$20.02, some valuation models flag an intrinsic discount of about 42%, but the stock is also facing slowing growth, legal questions and AI spending. Is this a reset opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 20.4% Undervalued

The most followed narrative on Doximity currently points to a fair value of about $25.15 against a last close of $20.02, framing the recent selloff as a valuation gap rather than a finished story.

The expanded adoption of AI-powered workflow tools (Scribe, Doximity GPT, and Pathway AI) is expected to further entrench Doximity as a core clinician productivity suite, driving frequency of platform use, deeper customer retention, and ultimately higher average revenue per user (ARPU) over time, supporting long-term revenue and margin expansion.

Curious what kind of revenue run rate, margin profile, and future earnings multiple need to line up to back that fair value estimate? The narrative leans on measured growth, resilient profitability and a specific future P/E that is lower than many peers. The exact mix of those assumptions might surprise you.

Result: Fair Value of $25.15 (UNDERVALUED)

However, this hinges on pharma marketing budgets holding up and on Doximity eventually monetising its free AI tools, both areas where outcomes could easily surprise you.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

If this mix of pressure and potential feels finely balanced, take a close look at the data now and weigh the company's 2 key rewards

Looking for more investment ideas?

If Doximity is on your radar, do not stop there. Broadening your watchlist now can help you spot opportunities that others might overlook.

• Target resilient balance sheets by scanning companies in the solid balance sheet and fundamentals stocks screener (47 results) that combine financial strength with established fundamentals.
• Hunt for value by checking out the 46 high quality undervalued stocks that flag stocks with quality metrics and potential pricing gaps.
• Prioritise steadier profiles by reviewing the 67 resilient stocks with low risk scores focused on companies with lower risk scores and more measured volatility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.